Sumitomo Pharma Oncology, Inc:Meet Our Team
Meet Our Team
HearfrompeoplewhoworkatSumitomoPharmaOncologyandlearnthetop10reasonswhypeoplelovenotjustworkingatSMPOncology,butmakingtheircareer ...。其他文章還包含有:「AboutUs」、「ClinicalPrograms」、「ContactUs」、「LeadershipTeam」、「News&Media」、「OurPipeline」、「Publications&Presentations」、「SumitomoPharmaOncology」、「SumitomoPharmaOncology」
查看更多 離開網站About Us
https://oncology.sumitomo-phar
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This ...
Clinical Programs
https://oncology.sumitomo-phar
Discover the science behind our early-stage research compounds in our clinical programs portfolio. Potential therapies include a protein binding inhibitor, ...
Contact Us
https://oncology.sumitomo-phar
Cambridge, MA ... Sumitomo Pharma Oncology, Inc. ... Sumitomo Pharma Oncology, Inc. 84 Waterford Drive Marlborough, MA 01752. Lehi, UT. Sumitomo Pharma Oncology, ...
Leadership Team
https://oncology.sumitomo-phar
Masashi Murata, Ph.D. Chief Strategy Officer Global Strategy and Planning. Read Bio.
News & Media
https://oncology.sumitomo-phar
Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage pharmaceutical company focused on research and development for novel cancer therapeutics, today ...
Our Pipeline
https://oncology.sumitomo-phar
Discover our pipeline of targeted therapies. Sumitomo Pharma Oncology is advancing cancer treatments for novel pathways in solid tumors and hematologic ...
Publications & Presentations
https://oncology.sumitomo-phar
Explore Sumitomo Pharma Oncology’s publications, abstracts, and presentations which outline ongoing clinical research and pipeline developments.
Sumitomo Pharma Oncology
https://www.linkedin.com
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This ...
Sumitomo Pharma Oncology
https://oncology.sumitomo-phar
Sumitomo Pharma Oncology is a global developer of novel cancer therapeutics dedicated to the promise of purposeful science in oncology.